Member Info for VP007

Shame we couldn’t hold above 10.5p today.

Would be great if TB dropped us a nice Xmas present RNS with sales to get this moving again!

If not, for the sake sanity, it is probably best to park this one and not look at the price on a daily basis. This is a medium term play for a product which has a large target market, is FDA approved and is platform agnostic. The latter point is key here and will open up the future revenue streams through Cloud.

Would be great if we can break over 10.5p and hold above this oday!

Watching patiently from the sidelines Kiwi.

Looking good and I’m holding strong.

Still under, but every little helps!

Great!
Let’s try and get back to the days high of 9.5p.

Baby steps on the journey back to 15p+

Great, good to get the perspective.

I’m still holding strong despite being a fair amount down, but a technology which is deemed the standard in the medical community and has FDA approval is definitely worth holding onto!

Hi Folks,

For the past few days I have seen 100k sells still going through which can’t be helping the share price.

Do we think TB is making more room to convert the remaining CLNs?

Hi All,

A bit of respite from the current conversations.

A while back Clairesmith found that a number of IB products were listed on the following AI marketplace as coming soon.

https://marketplace.arterys.com/

Apologies if this has already been posted, but it now appears that the IB models are now live on the AI marketplace.

It all helps that the IB products are getting further exposure with its distribution/channel partners.

Onwards and upwards for 2021.

The fact that the Mayo shares were issued at 13.21p is in my opinion a positive sign that this share is currently undervalued.

Mayo entered into a business agreement with IQAI and therefore they will expect a positive ROI on this.

I also think it is great that they have vested interest in making the next line of products a success.

Reads today’s RNS as follows:

“IQ-AI is confident that this release of SC Software is now positioned for widespread clinical adoption.”

- We have taken key potential clients feedback into the new software and they are now likely to buy

“IQ-AI has developed key technologies to tackle this growing concern. Of significance is an artificial intelligence (AI) model that accelerated IQ-AI's "gad-free" initiative”

- We have developed something unique that is also accelerating our internal research and development processes

“and will likely dovetail into processing stroke data.”

- not long left on the gad free initiative and the development teams are already geared up with the Mayo Clinic to deliver IB Stroke

“ IQ-AI continues to counter these issues by incorporating pre-processing technologies which ensure the quantitative integrity and appearance of processed data.”

- We have a USP over competitor algorithms and our 2020 developments are a solid foundation

“ Intelligently applying technology that efficiently and automatically presents clinicians with validated and proven output will remain a strategic initiative for IQ-AI, laying a pathway for a busy and exciting 2021.”

- we know the market share we are targeting in 2021 and the building blocks are now in place

“We believe retaining and developing StoneChecker will prove to be the right decision for IQAI shareholders”

- we have potential buyers lined up and this will be a revenue generator for us shortly

“ the developmental leaps made by IB in 2020 point to a very exciting 2021”

- hold onto your hat folks, 2021 is going to be a bumpy but exciting ride

“ The Directors of the Company accept responsibility for the contents of this announcement.”

- Have faith in the BoD :-))))))

.....something to lift the spirits from a challenging day!

According to this site there are a number of licensing options for the software:

https://grand-challenge.org/aiforradiology/product/imaging-biometrics-neuro/

Pricing model - Pay-per-use, Subscription, Traditional License Model (purchase plus annual maintenance)

Based on - Number of installations, Number of analyses

Drax - Agreed, they need to really start pushing the sales either directly or through their partners to really open up the revenue streams. Concern with their partners is that they are one of many products which are being offered and are often buried low down within the website. They need to get front and centre (potentially upgrading their own website to really bring home the benefits of the software and how they are leading the way in this area).

Just reading up on IB’s distribution partners and the Medimsight website shows a number of the IB products within the AI marketplace with a Cost Per Launch of 40USD.

Example below:
https://www.medimsight.com/studies/details?id=5695984180920320

Looking forward to future revenue figures as the company continues to build its offerings within the marketplace.

Many thanks.

I also agree we will have some strong news flow. My only reservation is whether the market makers will let this go on good news or limit price growth like they have on the last few RNS’s.

I guess we have not had sales figures yet, so the real shift in price is still to come.

Fingers crossed we hear something this side of Christmas.

Sharebel,

Really hoping to see a recovery here. I’m in since 16p so fairly under at the moment.

I still need to master when to buy (and sell) :-(

Hi All,

My Investing.com app is flagging that it is 5 days until earnings for IQAI.

Can anyone else validate if this correct?

Yes this does open up a lot of new opportunities for a Cloud subscription based service.

I think we can all agree that the current revenue on the half year report was not the largest, however the opportunity for growth with the recent developments is significant.

Do we know when they publish their annual report?

Yes sitting on a sizeable loss, but hope can make it back on the next tick up

Trevors closing statements in the 2020 annual report published May 2020 indicates IQ-AI are actively looking for mergers and acquisitions....watch this space...

https://www.proactiveinvestors.co.uk/LON:IQAI/IQ-AI-Limited/rns/815409

“As we move forward in 2020, we will continue to offer services to researchers who may need assistance in translating their research and technologies. Those services, whether software development, regulatory assistance, or marketing support, allows us to assess the commercialization potential of these new technologies for possible merger and/or acquisition opportunities.



Finally, we remain alert to the myriad of new companies creating innovative solutions that solve healthcare problems and aid patients. While we are excited about our organic growth potential, we recognize that merger and acquisition activity may accelerate revenue generation, fulfill technical gaps, and a potentially faster time to market. Expanding our footprint in medical imaging to better serve patients remains our unwavering goal, and we will remain aggressive in this pursuit.”

Found this website which highlights the IB Neuro distribution channels.

https://grand-challenge.org/aiforradiology/product/imaging-biometrics-neuro/

A few familiar names, but worth monitoring these partners. If they are being positive on social media, it will be a positive sign for IQ-AI.

“Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, Arterys, aycan Medical Systems, Pixmeo”

They have a number of products on the curated marketplace:

https://www.blackfordanalysis.com/application/imaging-biometrics/